FrancophonIA/ELRC3.0 huggingface dataset:
English: ImmunoGam contains 0.16 g of maltose in a 500 IU dose.
Maltese: ImmunoGam fih 0.16 g ta' maltose f'doża ta' 500
English: Store in a refrigerator (2 ºC to 8ºC).
Maltese: Aħżen fi friġġ (2ºC - 8ºC).
English: Uncommon (≥1/1,000 to <1/100) Uncommon (≥1/1,000 to <1/100) Uncommon (≥1/1,000 to <1/100)
Maltese: Mhux komuni (≥1/1,000 sa <1/100) Mhux komuni (≥1/1,000 sa <1/100) Mhux komuni (≥1/1,000 sa <1/100)
English: - The active substance is Human hepatitis B immunoglobulin.
Maltese: - Is-sustanza attiva hi Immunoglobulina tal-epatite B umana.
English: ImmunoGam 312 IU/ml solution for injection.
Maltese: ImmunoGam 312 IU/ml, soluzzjoni għall-injezzjoni.
English: Excipients: Maltose (see package leaflet for further information) and polysorbate 80
Maltese: Maltose (ara l-fuljett ta' tagħrif għal aktar informazzjoni) u polysorbate 80
English: The frequency of possible side effects listed below is defined using the following convension: - very common (affects more than 1 user in 10) - common (affects 1 to 10 users in 100) - uncommon (affects 1 to 10 users in 1,000) - rare (affects 1 to 10 users in 10,000) - very rare (affects less than 1 user in 10,000) - not known (frequency cannot be estimated from the available data)
Maltese: Il-frekwenza ta' effetti sekondarji possibbli elenkata hawn taħt hi definita bl-użu tal-konvenzjoni li ġejja: - komuni ħafna (jaffettwaw iktar minn utent 1 minn kull 10) - komuni (jaffettwaw minn 1 sa 10 utenti minn kull 100) - mhux komuni (jaffettwaw minn 1 sa 10 utenti minn kull 1,000) - rari (jaffettwaw minn 1 sa 10 utenti minn kull 10,000) - rari ħafna (jaffettwaw inqas minn utent 1 minn kull 10,000) - mhux magħruf (ma tistax tittieħed stima mid-data disponibbli)
English: ImmunoGam 312 IU/ml solution for injection
Maltese: ImmunoGam 312 IU/ml, soluzzjoni għall-injezzjoni
English: - Immunoprophylaxis of hepatitis B in haemodialysed patients: 8-12 IU/kg with a maximum of 500 IU, every 2 months until seroconversion following vaccination.
Maltese: - Immunoprofilassi ta' epatite B f'pazjenti emodijalizzati: 8-12 IU/kg b'massimu ta' 500
English: ImmunoGam contains a small quantity of IgA (less than 40 micrograms/ml).
Maltese: ImmunoGam fih kwantità żgħira ta' IgA (inqas minn 40 mikrogramma/ml).
English: Human hepatitis B immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against hepatitis B virus surface antigen (HBsAg).
Maltese: L-immunoglobulina tal-epatite B umana primarjament fiha immunoglobulina G (IgG) b'kontenut speċifikament għoli ta' antikorpi kontra antiġen tal-wiċċ tal-virus ta' epatite B (HBsAg).
English: Pharmacovigilance Plan or risk minimisation activities
Maltese: Farmakoviġilanza jew fuq l-attivitajiet ta' minimizzazzjoni tar-riskju;
English: Some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods) falsely interpret the maltose contained in ImmunoGam as glucose.
Maltese: Xi tipi ta' sistemi ta' ttestjar ta' glucose fid-demm (pereżempju, dawk ibbażati fuq il-metodi glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) jew glucose-dye-oxidoreductase) jinterpretaw b'mod falz il-maltose li jkun hemm f'ImmunoGam bħala glucose.
English: IgG and IgG-complexes are broken down in the reticuloendothelial system.
Maltese: IgG u kumplessi IgG jitkissru fiċ-ċelluli fis-sistema retikuloendoteljali.
English: The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 1.3 of the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP.
Maltese: Id-Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq huwa obbligat li jwettaq l-istudji u attivitajiet addizzjonali ta' farmakoviġilanza deskritti fil-Pjan tal-Farmakoviġilanza, kif maqbul f'verżjoni 1.3 tal-Pjan dwar lImmaniġġjar tar-Riskju (RMP) ippreżentat f'Modulu 1.8.2. tal-Applikazzjoni tal-Awtorizzazzjoni għat-Tqegħid fis-Suq, u kwalunkwe aġġornamenti sussegwenti tal-RMP li kienu maqbula mis-CHMP.
English: One vial contains 312 IU of anti-HBs in 1 ml One vial contains 1560 IU of anti-HBs in 5 ml
Maltese: Kunjett wieħed fih 312 IU ta' anti-HBs f'1 ml Kunjett wieħed fih 1560
English: At least 500 IU depending on the intensity of exposure, as soon as possible after exposure, and preferably within 24 - 72 hours every 2 months until seroconversion following
Maltese: IU skont l-intensità ta' espożizzjoni, kemm jista' jkun malajr wara espożizzjoni, u preferibbilment fi żmien 24 - 72 siegħa
English: These undesirable effects were reported within the first 7 days after receiving ImmunoGam: nausea, fatigue, induration (swelling and firmness) at the injection site, feeling unwell, pain, fever, joint pain, back pain, muscle pain, headache and dizziness.
Maltese: Dawn l-effetti mhux mixtieqa kienu rrappurtati matul l-ewwel 7 ijiem wara li persuna tkun irċeviet ImmunoGam: nawseja, għeja kbira, ebusija (nefħa u fermezza) fis-sit tal-injezzjoni, sensazzjoni li ma tħossokx tajjeb, uġigħ, deni, uġigħ fil-gogi, uġigħ fid-dahar, uġigħ fil-muskoli, uġigħ ta' ras u sturdament.
English: Each ml contains 312 IU Human Hepatitis B Immunoglobulin corresponding to a protein content of 30-70 mg/ml with at least 96% Immunoglobulin G (IgG).
Maltese: Kull ml fih 312 IU ta' Immunoglobulina tal-Epatite B Umana li jikkorrispondu għal kontenut ta' proteina ta' 30-70 mg/ml b'mill-inqas 96% ta' Immunoglobulina G (IgG).
English: Hypersensitivity to human immunoglobulins, especially in very rare cases of IgA deficiency when the patient has antibodies against IgA.
Maltese: Sensittività eċċessiva għal immunoglobulini umani, speċjalment f'każijiet rari ħafna ta' defiċjenza ta' IgA, meta l-pazjent ikollu antikorpi kontra
English: - Immunoprophylaxis of hepatitis B in haemodialysed patients:
Maltese: - Immunoprofilassi ta' epatite B f'pazjenti emodijalizzati:
English: For safety with respect to transmissible agents, see section 4.4
Maltese: Għas-sigurtà fir-rigward ta' aġenti trasmissibbli, ara sezzjoni 4.4.
English: HOW TO STORE IMMUNOGAM
Maltese: ImmunoGam jintuża
English: Please tell your doctor immediately if you experience any of the following symptoms after o hives, flushed skin or rash, swelling of a specific area such as the injection site or face o chest tightness, shortness of breath, wheezing o rapid increase in heart beat, sudden drop in blood pressure and/or shock These symptoms may be early signs of an allergic reaction.
Maltese: Jekk jogħġbok għid lit-tabib tiegħek immedjatament jekk ikollok kwalunkwe sintomi wara li tirċievi o urtikarja, ġilda ħamra jew raxx, nefħa ta' żona speċifika bħal fis-sit tal-injezzjoni jew fil-wiċċ o dwejjaq fis-sider, qtugħ ta' nifs, tħarħir o żieda mgħaġġla fit-taħbit tal-qalb, tnaqqis għal għarrieda fil-pressjoni tad-demm u/jew xokk Dawn kollha jistgħu jkunu sinjali ta' reazzjoni allerġika.
English: Undesirable effects reported during clinical trials with ImmunoGam, that was administered intramuscularly (injected into a muscle), were uncommon (affects 1 to 10 users in 1,000).
Maltese: L-effetti mhux mixtieqa rrappurtati matul il-provi kliniċi b'ImmunoGam, li ngħata ġol-muskoli (ġie injettat ġo muskolu) u li kienu kkunsidrati li kienu marbuta ma' ImmunoGam, kienu mhux komuni (li jaffettwaw minn 1 sa 10 utenti minn kull 1,000).
English: Repeated-dose toxicity testing and embryo-fetal toxicity studies are impractical due to induction of, and interference with antibodies.
Maltese: L-ittestjar dwar it-tossiċità ta' dożi ripetuti u t-tossiċità embrijo-fetali mhumiex prattikabbli minħabba l-induzzjoni ta', u l-interferenza mal-antikorpi.
English: The measures taken are considered effective for enveloped viruses such as HIV, HBV, and HCV.
Maltese: Il-miżuri meħuda huma kkunsidrati li huma effettivi għal viruses enveloped bħal HIV, HBV u HCV.
English: Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations, and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses.
Maltese: Miżuri standard biex jiġu evitati infezzjonijiet li jirriżultaw mill-użu ta' prodotti mediċinali ppreparati minn demm jew plażma umana jinkludu l-għażla tad-donaturi, screening ta' donazzjonijiet individwali u ta' pools tal-plażma għal markaturi speċifiċi ta' infezzjoni u l-inklużjoni ta' miżuri effettivi fil-proċess tal-manifattura għall-inattivazzjoni/tneħħija ta' viruses.
English: * Frequency has been evaluated using the following criteria: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100).
Maltese: * Il-frekwenza kienet stabbilita billi intużaw il-kriterji li ġejjin: komuni ħafna (≥1/10); komuni (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100).
English: The measures taken may be of limited value against non-enveloped viruses such as hepatitis A virus and parvovirus B19.
Maltese: Il-miżuri li jittieħdu jista' jkollhom effett limitat kontra viruses non-enveloped bħal virus tal-epatite A u parvovirus B19.
English: ImmunoGam comes in a 1 ml or 5 ml vial containing 30-70 mg/ml of human plasma protein of which 96% (312 IU/ml) is Immunoglobulin G (IgG).
Maltese: ImmunoGam jiġi f'kunjett ta' 1 ml jew 5 ml li jkun fih 30-70 mg/ml ta' proteina tal-plażma umana, li minnha 96% (312 IU/ml) hi
English: • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
Maltese: • Fiż-żmien 60 jum minn meta jintlaħaq għan importanti (farmakoviġilanza jew minimizzazzjoni tar-riskju);
English: • Human hepatitis B immunoglobulin injections can induce a drop in blood pressure with an allergic reaction, even in patients who have tolerated previous treatments with immunoglobulin.
Maltese: • L-injezzjonijiet tal-immunoglobulina tal-epatite B umana jistgħu jikkaġunaw tnaqqis fil-pressjoni taddemm b'reazzjoni allerġika, anki f'pazjenti li ttolleraw kuri bl-immunoglobulina fil-passat.
English: There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to
Maltese: Hemm esperjenza klinika rassiguranti dwar in-nuqqas ta' trasmissjoni ta' epatite A jew parvovirus B19 b'immunoglobulini, u hu ssoponut ukoll li l-kontenut tal-antikorpi jagħti kontribut importanti lis-sigurtà virali.
English: ImmunoGam contains increased levels of human hepatitis B immunoglobulins mainly immunoglobulin G (IgG) and is obtained from blood plasma of screened donors from
Maltese: ImmunoGam fih livelli miżjuda ta' immunoglobulini tal-epatite B umana, primarjament immunoglobulina G (IgG), u jinkiseb mill-plażma fid-demm ta' donaturi mill-Istati Uniti tal-Amerika li jkunu ġew skrinjati.
English: A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Maltese: MANIFATTUR TAS-SUSTANZA BIJOLOĠIKA ATTIVA U DETENTUR TA' L-AWTORIZZAZZJONI TAL-MANIFATTURA
English: [Justification for not including Braille accepted]
Maltese: [Il-ġustifikazzjoni biex ma jkunx inkluż il-Braille hija aċċettata]
English: The immunoglobulin IgG subclasses are:
Maltese: • Immunoglobulina A:
English: In case of shock, standard medical treatments for shock should be implemented.
Maltese: F'każ ta' xokk, il-kura medika standard għal xokk għandha tkun implimentata.
English: Immunoglobulins are normal constituents of the human body.
Maltese: L-immunoglobulini huma komponent normali fil-ġisem tal-bniedem.
English: Store in a refrigerator (2 to 8
Maltese: Aħżen fi friġġ (2
English: The measures taken may be of limited value against non-enveloped viruses such as HAV and parvovirus B19.
Maltese: Il-miżuri li jittieħdu jista' jkollhom effett limitat kontra viruses non-enveloped bħal HAV u parvovirus B19.
English: Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective.
Maltese: L-immunoglobulini ma kinux assoċjati ma' infezzjonijiet ikkawżati minn epatite A jew parvovirus B19, possibbilment minħabba li l-antikorpi kontra dawn l-infezzjonijiet, li jinsabu fil-prodott, huma protettivi.
English: In subjects who did not show an immune response (no measurable hepatitis B antibodies) after vaccination, and for whom continuous prevention is necessary, administration of 500 IU to adults and 8 IU/kg to children every 2 months can be considered; a minimum protective antibody titre is considered to be 10 mIU/ml.
Maltese: IU lil adulti u 8 IU/kg lit-tfal kull xahrejn jista' jiġi kkunsidrat; titre ta' antikorp protettiv minimu hu kkunsidrat li hu 10 mIU/ml.
English: - In subjects who did not show an immune response (no measurable hepatitis B antibodies) after vaccination and for whom a continuous prevention is necessary due to the continuous risk of being infected with hepatitis B.
Maltese: - F'persuni li ma wrewx rispons immuni (l-ebda antikorpi għal epatite B li jistgħu jitkejlu) wara t-tilqima u li għalihom il-prevenzjoni kontinwa hi meħtieġa minħabba r-riskju kontinwu li jiġu infettati b'epatite B.
English: In general for immunoglobulin products, adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Maltese: B'mod ġenerali għal prodotti b'immunoglobulini, reazzjonijiet avversi bħal tertir ta' bard, uġigħ ta' ras, deni, rimettar, reazzjonijiet allerġiċi, nawseja, artralġja, pressjoni tad-demm baxxa u wġigħ moderat fin-naħa t'isfel tad-dahar jistgħu jseħħu kultant.
English: • Immunoglobulin A: Please tell your doctor if your blood does not have immunoglobulin A (IgA).
Maltese: • M'hemm l-ebda dejta disponibbli dwar l-interazzjonijiet ta' ImmunoGam ma' mediċini oħrajn.
English: As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
Maltese: Skont il-Linja Gwida CHPM dwar is-Sistemi tal-Immaniġġjar tar-Riskju għal prodotti mediċinali għall-użu uman, l-RMP aġġornat għandu jkun sottomess fl-istess ħin mar-Rapport Perjodiku dwar l-Aġġornament tasSigurtà (Periodic Safety Update Report - PSUR) li jkun imiss.
English: ImmunoGam is supplied in a Type 1 glass vial with a siliconized bromobutyl rubber stopper, aluminum seal and
Maltese: ImmunoGam hu fornut f'kunjett tal-ħġieġ ta' Tip I, b'tapp tal-lastku ta' siliconized bromobutyl, siġill tal-aluminju u għatu tal-plastik flip-off.
English: • Immunoglobulins in general may cause adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia (joint pain), low blood pressure and moderate low back pain.
Maltese: rimettar, reazzjonijiet allerġiċi, nawseja, artralġja (uġigħ fil-ġogi), pressjoni tad-demm baxxa u wġigħ
English: Take special care with ImmunoGam General warnings related to ImmunoGam:
Maltese: - Prevenzjoni ta' epatite B f'każ ta' espożizzjoni aċċidentali f'persuni mhux imlaqqma:
English: Official batch release: in accordance with Article 114 Directive 2001/83/EC as amended, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
Maltese: Ħruġ tal-lott uffiċjali: skont Artiklu 114 tad-Direttiva 2001/83/KE kif emendata, il-ħruġ tal-lott uffiċjali jsir minn laboratorju tal-Istat jew laboratorju ieħor li jiġi maħtur għal dak il-għan.
English: BEFORE YOU RECEIVE IMMUNOGAM
Maltese: ImmunoGam fih ammonti żgħar ta' IgA.
English: 8-12 IU/kg with a maximum of 500 IU, every 2 months until seroconversion following vaccination.
Maltese: 8-12 IU/kg b'massimu ta' 500
English: The MAH must ensure that the system of pharmacovigilance, as described in version 2.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on
Maltese: Id-Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq irid jiżgura li s-sistema ta' farmakoviġilanza, kif deskritta f'verżjoni 2.0 ippreżentata f'Modulu 1.8.1. tal-applikazzjoni għall-awtorizzazzjoni għat-tqegħid fis-suq tkun fisseħħ u tiffunzjona qabel u waqt li l-prodott ikun fuq is-suq.
English: You should NOT be given ImmunoGam - if you have previously developed an allergic reaction to human immunoglobulins, to other blood products or to any of the other ingredients of ImmunoGam.
Maltese: M'GĦANDEKX tingħata ImmunoGam - jekk fil-passat tkun żviluppajt reazzjoni allerġika għal immunoglobulini umani, għal prodotti oħrajn tad demm jew għal kwalunkwe ingredjenti oħrajn ta' ImmunoGam.
English: Rarely, human hepatitis B immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who have tolerated previous treatment with immunoglobulin.
Maltese: B'mod rari, l-immunoglobulina tal-epatite B umana tista' tikkaġuna tnaqqis fil-pressjoni tad-demm b'reazzjoni anafilattika, anki f'pazjenti li ttolleraw kura b'immunoglobulina fil-passat.
English: ImmunoGam should be brought to room temperature (approximately 20 ºC to 25ºC) before use.
Maltese: ImmunoGam għandu jitħalla jilħaq it-temperatura tal-kamra (madwar 20°C sa 25°C) qabel l-użu.
English: The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus.
Maltese: Il-miżuri li jittieħdu huma kkunsidrati li huma effettivi għal viruses enveloped bħal virus tal-immunodefiċjenza umana (HIV), il-virus tal-epatite B u l-virus tal-epatite Ċ.
English: ImmunoGam provides protection against hepatitis B virus for a short period of time and it is used to treat the
Maltese: ImmunoGam jipprovdi protezzjoni kontra l-virus tal-epatite B għal perjodu qasir ta' żmien.
English: Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines such as rubella, mumps, measles and varicella for a period of 3 months.
Maltese: L-għoti tal-immunoglobulini jista' jinterferixxi mal-iżvilupp ta' rispons immuni għal tilqim b'virus ħaj attenwat, bħal ħosba Ġermaniża, gattone, ħosba, u l-ġidri r-riħ għal perjodu ta' 3 xhur.
English: This is because Some types of blood glucose testing systems falsely interpret the maltose contained in ImmunoGam as glucose.
Maltese: Dan hu minħabba li xi tipi ta' sistemi ta' ttestjar ta' glucose fid-demm jinterpretaw b'mod falz il-maltose li jkun hemm f'ImmunoGam bħala glucose.
English: • Patients should be monitored for antibodies against human hepatitis B immunoglobulin regularly.
Maltese: • Il-pazjenti għandhom jiġu mmonitorjati għal antikorpi kontra l-immunoglobulina tal-epatite B umana
English: This may result in falsely elevated glucose readings and consequently in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia.
Maltese: Dan jista' jirriżulta f'riżultati għolja foloz talglucose u konsegwentement fl-għoti ta' insulina li ma jkunx adattat, li jirriżulta f'ipogliċemija.
English: - Newborn of a hepatitis B virus carrier-mother.
Maltese: - Fit-tarbija tat-twelid ta' omm li jkollha virus tal-epatite B.
English: Patients who have an IgA deficiency may develop an allergic reaction to this medicine.
Maltese: Hemm ċans li jista' jkollok reazzjoni allerġika wara l-għoti ta' dan mediċina.
English: Human hepatitis B immunoglobulin for intramuscular use is bioavailable in the recipient's circulation after a delay of 2 - 3 days.
Maltese: Immunoglobulina tal-epatite B umana għall-użu ġol-muskoli hi bijodisponibbli fiċ-ċirkolazzjoni tal-pazjent wara dewmien ta' 2 - 3 ijiem.
English: What ImmunoGam looks like and contents of the pack
Maltese: Id-dehra ta' ImmunoGam u l-kontenuti tal-pakkett
English: If a large volume (greater than 2 ml for children or greater than 5 ml for adults) is required, it is recommended that the administration of ImmunoGam be divided doses at different sites.
Maltese: Jekk volum kbir (iktar minn 2 ml għat-tfal jew iktar minn 5 ml għall-adulti) ikun meħtieġ, hu rakkomandat li l-għoti ta' ImmunoGam jingħata f'dożi maqsuma f'siti differenti.
English: - Keep this leaflet.
Maltese: Prevenzjoni ta' epatite B f'każ ta' espożizzjoni
English: Frequency of Administration
Maltese: KLASSIFIKAZZJONI ĠENERALI
English: Related undesirable effects within 7 days of ImmunoGam administration, from clinical trials conducted using the intramuscular route of administration is tabulated below:
Maltese: Effetti mhux mixtieqa relatati li jseħħu fi żmien 7 ijiem mill-għoti ta' ImmunoGam, minn provi kliniċi li saru blużu tal-għoti ġol-muskoli, qed jintwerew hawn taħt:
English: Name and address of the manufacturers responsible for batch release
Maltese: U DETENTUR TA' LAWTORIZZAZZJONI TAL-MANIFATTURA RESPONSABBLI
English: CAPSULE, HARD ORAL USE
Maltese: KAPSULA, IEBSA UŻU ORALI
English: Strides Arcolab International Limited
Maltese: Id-Danimarka Strides Arcolab International Limited
English: United Kingdom Pfizer Limited
Maltese: Pfizer Limited
English: United Kingdom Nrim Limited
Maltese: Nrim Limited
English: United Kingdom Morningside Healthcare Ltd
Maltese: Morningside Healthcare Ltd
English: DIRECT INTRAVENOUS INJECTION
Maltese: INJEZZJONI INTRAVOSTA
English: United Kingdom Laboratorio Reig Jofre, S.A.
Maltese: Laboratorio Reig Jofre, S.A.
English: United Kingdom Co-Pharma Limited Vancomycin CoPharma
Maltese: Co-Pharma Limited Vancomycin CoPharma
English: INFUSION
Maltese: INFUSJONI
English: ANNEX I
Maltese: Anness I
English: Pliva Hrvatska D.O.O.
Maltese: Pliva Hrvatska
English: Laboratórios Azevedos - Indústria Farmacêutica, S.A.
Maltese: Laboratórios AzevedosIndústria Farmacêutica, S.A.
English: Pharmatex Italia Srl Vancotex
Maltese: Pharmatex Italia Srl
English: Teva Denmark A-S Vancomycin Teva VANCOMYCIN HYDROCHLORIDE
Maltese: Id-Danimarka Teva Denmark A-S Vancomycin Teva VANKOMIĊINA IDROKLORIDU
English: Vanco-Ratiopharm VANCOMYCIN HYDROCHLORIDE
Maltese: Vanco-Ratiopharm VANKOMIĊINA IDROKLORIDU
English: Mip Pharma Austria Gmbh
Maltese: Mip Pharma Austria
English: Vancomycin φοινιξφαρμ
Maltese: Vancomycin φοινιξφαρμ il-greċja
English: POWDER FOR INJECTION
Maltese: PRAŠEK ZA RAZTOPINO ZA INJICIRANJE
English: VANCOMYCIN HYDROCHLORIDE 500000 I.U.
Maltese: VANKOMIĊINA IDROKLORIDU 500000 I.U.
English: Hospira Benelux Vancomycin Hospira VANCOMYCIN
Maltese: Hospira Benelux Bvba Vancomycin Hospira
English: Vancomycin Hydrochloride Pharmaceutical
Maltese: Vancomycin Hydrochloride Pharmaceutical Trading
English: Vancomycine Teva VANCOMYCIN HYDROCHLORIDE 1G
Maltese: Vancomycine Teva Vankomiċina IDROKLORIDU 1G
English: VANCOMYCIN HYDROCHLORIDE 512.571MG UNITS
Maltese: VANKOMIĊINA IDROKLORIDU 512.571MG UNITS
English: VANCOMYCIN HYDROCHLORIDE 128.15MG CAPSULE
Maltese: VANKOMIĊINA IDROKLORIDU 128.15MG KAPSULA
English: Vancomycin Actavis Group
Maltese: Vancomycin Actavis
English: Eli Lilly Italia S.P.A. Vancocina A.P.
Maltese: Eli Lilly Italia S.P.A.
English: Vancomycine Teva VANCOMYCIN 1000MG/20 ML
Maltese: Vancomycine Teva VANKOMIĊINA 1000MG/20
English: VANCOMYCIN HYDROCHLORIDE 1025MG/1025 MG
Maltese: VANKOMIĊINA IDROKLORIDU 1025MG/1025
English: VANCOMYCIN 1000 mg per vial
Maltese: VANKOMIĊINA 1000 mg per kunjett
English: Hospira Portugal Lda Vancomycin Hospira VANCOMYCIN HYDROCHLORIDE
Maltese: Hospira Portugal Lda Vancomycin Hospira
English: Generics [uk] Limited Vancomycin Mylan VANCOMYCIN 1000MG VIAL
Maltese: Generics [uk] Limited Vancomycin Mylan VANKOMIĊINA 1000MG KUNJETT
English: Vancomycine Teva VANCOMYCIN 500MG/10 ML
Maltese: Vancomycine Teva VANKOMIĊINA 500MG/10 ML
English: Mip Pharma Gmbh Bactocin
Maltese: Id-Danimarka Mip Pharma Gmbh Bactocin
English: España S.A.U.
Maltese: Italia S.P.A.
English: Generics [uk] Limited Vancomycin Mylan VANCOMYCIN 500MG VIAL
Maltese: Generics [uk] Limited Vancomycin Mylan VANKOMIĊINA 500MG KUNJETT
English: 1026MG Vial
Maltese: 1026MG KUNJETT
English: Pharmaserve-Lilly Saci
Maltese: Pharmaserve-Lilly Saci Voncon il-greċja
English: Noridem Enterprises Ltd
Maltese: Enterprises Ltd.
English: VANCOMYCIN HYDROCHLORIDE 500MG/500 MG
Maltese: Vankomiċina IDROKLORIDU 500MG/500 MG